ACH-3102

DRUG2 trials

Sponsors

Alexion Pharmaceuticals, Inc., Alios Biopharma Inc.

Conditions

Chronic Hepatitis CHepatitis C, Chronic

Phase 1

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

CompletedNCT02512562

Alios Biopharma Inc.Chronic Hepatitis C

Start: 2015-07-31End: 2015-08-31Updated: 2019-10-16

Phase 2

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

CompletedNCT01849562

Alexion Pharmaceuticals, Inc.Hepatitis C, Chronic

Start: 2013-04-30End: 2014-04-30Updated: 2023-08-29

Related Papers

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

2020-02-173 citations

Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.

2018-10-22